| 1 Global: Clinical efficacy ‐ significant reduction in ESRS scores from baseline |
2 |
65 |
Risk Ratio (M‐H, Fixed, 95% CI) |
19.97 [2.87, 139.19] |
| 2 Global 1. Average endpoint dose of pyridoxal 5 phosphate |
|
|
Other data |
No numeric data |
| 3 Global: 2. Other adverse effects than tardive dyskinesia |
2 |
65 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.97 [0.20, 78.59] |
| 4 Global: 3. Discontinuation of Vitamin B6 |
2 |
65 |
Risk Ratio (M‐H, Fixed, 95% CI) |
8.72 [0.51, 149.75] |
| 5 Tardive dyskinesia: 1. Deterioration in tardive dyskinesia symptoms |
2 |
65 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.16 [0.01, 3.14] |
| 6 Tardive dyskinesia: 2. Average endpoint ESRS tardive dyskinesia scores |
2 |
60 |
Mean Difference (IV, Fixed, 95% CI) |
‐4.07 [‐6.36, ‐1.79] |
| 7 General Mental State: Average endpoint positive psychiatric symptoms score |
1 |
15 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.50 [‐4.80, 1.80] |
| 8 General mental state: Average endpoint negative psychiatric symptoms score |
1 |
15 |
Mean Difference (IV, Fixed, 95% CI) |
‐1.10 [‐5.92, 3.72] |
